An experimental COVID-19 vaccine under development by pharma giant Pfizer and U.S. firm BioNTech has proven effective at producing neutralizing antibodies, the companies announced Wednesday.
Pfizer and BioNTech said in a study that all 24 participants in an early-phase clinical trial who received lower dose levels of the vaccine candidate, BNT162b1, generated antibodies against the coronavirus that causes COVID-19.
Some of the antibodies were found to be “neutralizing,” or sufficiently powerful to halt the virus, the research states.
The level of “neutropenia” necessary to provide immunity, however, is not yet known and must be determined in a larger safety and efficacy trial scheduled for July.
